ASTECAstec LifeSciences Limited
Metals · Agricultural Inputs · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maize, as well as grains, such as barley, rice, and wheat; post-harvest drench; and food additive and wood preservatives. It also provides herbicides, insecticides, and specialty chemical products. The company also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited operates as a subsidiary of Godrej Agrovet Limited.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why avoid
- • Overall evidence is weak (AlgoScore 33/100)
- • Revenue growth: -8.3% YoY
- • ROE: -20.7%
- • RSI: 40
- • MACD: bearish
⚖️ 1 bullish pattern setup is currently active on this stock. Pattern setup-quality percentages measure how cleanly a chart formation developed — they are not an endorsement of the company. Short-term traders may still trade those setups with strict stops; the AVOID verdict reflects the overall risk/fundamental profile for holding.
Bull case
- • Profit growth: 39.9% YoY
- • Promoter holding: 73.1%
- • Golden cross setup: SMA50 above SMA200
- • Supertrend: bullish
Bear case
- • Revenue growth: -8.3% YoY
- • ROE: -20.7%
- • RSI: 40
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Revenue growth: -8.3% YoY
- • ROE: -20.7%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹39.25). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.